Search - tctmd.com

Displaying 241 - 260 of 317

Sort: Relevancy | Date

Presentation TCT 2015

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

Presenter: Eberhard Grube, Michael J. Mack

October 11, 2015

Presentation TCT 2015

TAVR is a Breakthrough Technology: Important Milestones and Emerging Controversies

Presenter: Eberhard Grube, Michael J. Mack, Raj Makkar

October 11, 2015

Presentation TCT 2015

Introduction

Presenter: Eberhard Grube, Michael J. Mack, Martin B. Leon

October 11, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

L.A. McKeown

October 08, 2015

News Daily News

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

L.A. McKeown

October 08, 2015

Presentation ACC 2015

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Presenter: Michael J. Mack

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

News Daily News

Most Late Cardiac Mortality After TAVR Due to Heart Failure, Sudden Cardiac Death

Yael L. Maxwell

February 02, 2015

News Features TCT 2014

Thoughtful Insights at TCT: Many Questions Remain Around Treatment of Valvular Disease

Todd Neale

October 24, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Michael J. Mack

September 17, 2014

Presentation TCT 2014

Are the Current Clinical Trial Pathways for New Mitral Valve Therapies Practical? A Future Roadmap to Consider!

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Francesco Maisano, Gregg W. Stone

September 16, 2014

Presentation TCT 2014

Mitral Valve Repair vs Replacement: Complementary or Competitive?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Francesco Maisano

September 16, 2014

Presentation TCT 2014

TAVR Controversies: Strokes and Paravalvular Regurgitation Will New TAVR Systems or Accessory Devices Make a Difference?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Daniel I. Simon, Samir R. Kapadia

September 16, 2014

Presentation TCT 2014

Regulatory Approval Pathways for Novel vs Iterative TAVR Devices: Back to the Future?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Daniel I. Simon, Nicole Ibrahim

September 16, 2014

Presentation TCT 2014

A Golden Year for TAVR - Accomplishments, Controversies, and Future Directions

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Daniel I. Simon, Martin B. Leon

September 16, 2014

Presentation TCT 2014

Clinical Indications for TAVR: Where are We and Where are We Going?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Daniel I. Simon, A. Pieter Kappetein

September 16, 2014

Presentation TCT 2014

Con: Ignore Aortic Regurgitation at Your Own Risk!

Presenter: Simon Redwood, Michael J. Mack

September 15, 2014

Presentation TCT 2014

The Trial Got it Right: Replacement Is Favored in Functional MR!

Presenter: Michael J. Mack

September 14, 2014

News Conference News TCT 2014

Lively Debate on Use of TAVR for Lower-Risk Patients

September 14, 2014

Advertisement

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

TAVR is a Breakthrough Technology: Important Milestones and Emerging Controversies

Introduction

Global TAVR Market Poised to Exceed DES Market by 2025

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Most Late Cardiac Mortality After TAVR Due to Heart Failure, Sudden Cardiac Death

Thoughtful Insights at TCT: Many Questions Remain Around Treatment of Valvular Disease

Thoughtful Insights

Are the Current Clinical Trial Pathways for New Mitral Valve Therapies Practical? A Future Roadmap to Consider!

Mitral Valve Repair vs Replacement: Complementary or Competitive?

TAVR Controversies: Strokes and Paravalvular Regurgitation Will New TAVR Systems or Accessory Devices Make a Difference?

Regulatory Approval Pathways for Novel vs Iterative TAVR Devices: Back to the Future?

A Golden Year for TAVR - Accomplishments, Controversies, and Future Directions

Clinical Indications for TAVR: Where are We and Where are We Going?

Con: Ignore Aortic Regurgitation at Your Own Risk!

The Trial Got it Right: Replacement Is Favored in Functional MR!

Lively Debate on Use of TAVR for Lower-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content